BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25854120)

  • 21. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Asnafi V; Rubio MT; Delabesse E; Villar E; Davi F; Damaj G; Hirsch I; Dhédin N; Vernant JP; Varet B; Buzyn A; Macintyre E
    Leukemia; 2006 May; 20(5):793-9. PubMed ID: 16541140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
    Tiribelli M; Bonifacio M; Calistri E; Binotto G; Maino E; Marin L; Guardalben E; Branca A; Gherlinzoni F; Semenzato G; Sancetta R; Pizzolo G; Fanin R
    Leuk Res; 2013 Nov; 37(11):1457-60. PubMed ID: 23993428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia.
    van Rhee F; Lin F; Cross NC; Reid CD; Lakhani AK; Szydlo RM; Goldman JM
    Bone Marrow Transplant; 1994 Oct; 14(4):609-12. PubMed ID: 7858536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic granulocytic leukaemia. A study of 160 cases.
    Kumar L; Sagar TG; Maitreyan V; Majhi U; Shanta V
    J Assoc Physicians India; 1990 Dec; 38(12):899-902. PubMed ID: 2096123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute leukaemoid reaction following cardiac surgery.
    Drury NE; Ali A; Mussa S; Webb ST; Rege KP; Wallwork J
    J Cardiothorac Surg; 2007 Jan; 2():3. PubMed ID: 17212818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of the chronic leukemias: special considerations in the elderly patient. Part III rarer chronic myeloid leukemias.
    Spiers AS
    Hematology; 2002 Feb; 7(1):1-8. PubMed ID: 12171771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
    Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
    Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
    Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
    Tiribelli M; Binotto G; Calistri E; Maino E; Scaffidi L; Medeot M; Nabergoj M; Ambrosetti A; Semenzato G; Fanin R; Bonifacio M;
    Am J Hematol; 2015 Jul; 90(7):E135-7. PubMed ID: 25808917
    [No Abstract]   [Full Text] [Related]  

  • 33. [Long-term survival in chronic myeloid leukemia: frequency and fundamental characteristics in a series of 100 patients].
    Cervantes F; Bosch F; Terol MJ; Pereira A; Rozman C
    Sangre (Barc); 1993 Apr; 38(2):93-6. PubMed ID: 8516734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up study of patients diagnosed with chronic myelogenous leukemia treated with STI 571 in Ecuador.
    Paz-Y-Miño C; Arévalo M; Sánchez ME; Cañizares C; Leone PE
    Arch Med Res; 2007 Apr; 38(3):364-5. PubMed ID: 17350491
    [No Abstract]   [Full Text] [Related]  

  • 36. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
    Melo JV; Myint H; Galton DA; Goldman JM
    Leukemia; 1994 Jan; 8(1):208-11. PubMed ID: 8289491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT.
    Reiffers J; Goldman J; Meloni G; Cahn JY; Gratwohl A
    Bone Marrow Transplant; 1994 Sep; 14(3):407-10. PubMed ID: 7994263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-emerging Philadelphia chromosome-positive acute leukaemia more than 20 years after allogeneic haematopoietic stem cell transplantation.
    Kodama Y; Okamura J; Fukano R; Nakashima K; Ito N; Nishimura M; Abe Y; Suzuki T; Inagaki J
    Br J Haematol; 2013 Apr; 161(2):286-9. PubMed ID: 23294201
    [No Abstract]   [Full Text] [Related]  

  • 39. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Hochhaus A; Saussele S; Rosti G; Mahon FX; Janssen JJWM; Hjorth-Hansen H; Richter J; Buske C;
    Ann Oncol; 2017 Jul; 28(suppl_4):iv41-iv51. PubMed ID: 28881915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.